Trial Profile
Safety and efficacy of amrubicin in patients with non-small cell lung cancer: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2019
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2018 Results published in the Oncology Research and Treatment
- 27 May 2016 New trial record
- 01 Apr 2016 Results published in the Journal of Thoracic Oncology